Cenedella.de

Patient Advocate since 1977.


Leave a comment

Isodiol sets up operations in Mexico to begin shipping cannabis products and are now working on a manufacturing permit to produce medical marijuana with less than 1% THC

VANCOUVER — Isodiol International Inc., a developer of cannabis products for the pharmaceutical and consumer markets, has established operations in Mexico.

Mexico has officially legalized medical marijuana with less than 1% THC.

The Vancouver-based company has invested in infrastructure to expand its distribution into the market.

“Through our online sales platform, we will immediately be able to commence distribution and build a footprint within Mexico,” said Marcos Agramont, the company’s CEO and director. “We will also continue to work through the approval process with Comision Federal para la Proteccion contra Riesgos Sanitarios for our manufacturing permit which will allow us to produce in Mexico.”


Leave a comment

ASA’s Patient Focused Certification (PFC) program is now leading the development of international regulatory guidelines, presenting to public health officials and industry stakeholders around the globe, conducting trainings in the US and abroad, and partnering with the University of Maryland’s School of Pharmacy on cannabis education.

PFC at Forefront of International Standards Development

ASA’s effort to set scientifically sound standards for cannabis safety and quality has found new partners and gone international. ASA’s Patient Focused Certification (PFC) program is now leading the development of international regulatory guidelines, presenting to public health officials and industry stakeholders around the globe, conducting trainings in the US and abroad, and partnering with the University of Maryland’s School of Pharmacy on cannabis education.

Spearheading the effort is ASA’s chief scientist Jahan Marcu, PhD, in his role as a director of the PFC program. Just this past month, Dr. Marcu has crisscrossed the globe collaborating with doctors, scientists and public health officials from Spain to Israel to Mexico and back, plus conducting trainings in Ohio and Florida.

In Spain, PFC certified the country’s first cannabis distributor, worked with a doctor’s office, and conducted a weeklong training attended by representatives from 10 countries.

In Mexico, Dr. Marcu (pictured at right with patients and advocates in Mexico City) met with officials from the Department of Health and presented a talk on medical cannabis at the invitation of the national institute of pediatrics. PFC is translating ASA’s educational materials into Spanish and will be training the country’s health officials through the Cannabis Care Certification program on how to draft and implement sound regulation. PFC has also been asked to work with the governor’s office in Mexico City on drafting health and safety guidelines.

In Israel, Dr. Marcu made two presentations to Cann10, the second international medical cannabis conference in Tel Aviv. The focus there is on matching cannabis varieties to individual patients based on matching human genetics to plants. PFC’s Cannabis Care Certification will be training physicians in Israel, and manufacturing companies there have applied to PFC for certification.

In the U.S., PFC has been offering webinars and in-person trainings, including a CME event in Orlando, Florida for health care professionals and a training in Ohio. Dr. Marcu was also invited to speak about the PFC program at the American Public Health Laboratory conference last month. He will be speaking about the endocannabinoid system this month at the Cannabis World Congress and Expo in New York and presenting on international cultivation standards this month as part of the annual meeting of the International Cannabinoid Research Society (ICRS), held this year in Montreal, Quebec.

PFC’s role in developing regulatory guidance will be central, as Dr. Marcu is chairing the ASTM subcommittee of 50 experts developing standards for education and training and criteria for regulatory assessment. These standards will determine how the cannabis industry will function – who gets licenses, who gets trained and how.

PFC’s new partnership with the University of Maryland School of Pharmacy launches next week at PFCtraining.org. This will be the only cannabis training program available through a university online for credit. Going forward, the University of Maryland will be conducting educational trainings, while Dr. Marcu and the PFC staff will handle regulatory issues and compliance.

PFC webinars are being run about every two weeks. Some are free, and those with fees are available to patients on a sliding scale. Interested patients should email PFC ahead of the webinar they’d like to attend.

PFC began with a collaborative effort with the American Herbal Products Association (AHPA) and the American Herbal Pharmacopoeia (AHP), but the international nature of medical cannabis research and development has transformed it into a global project.

US Attorney General Jeff Sessions – “How To Spot A Stoner”

Leave a comment


Leave a comment

Patent 6630507: Exposing the Truth and Impact to the Pot Industry

Patent 6630507: Exposing the Truth and Impact to the Pot Industry

WASHINGTON, DC – Having a patent under your name means owning an intellectual property set upon the grounds and regulations of the agency governing it.

Not all people are familiar and well-versed with the scopes of patents, this is why it is easier for some to spread misinformation regarding the importance of one patent and its general use.

This is what happened when Patent no. 6630507 trended and had been shared in multiple social media accounts with different claimants, representations, and explanations on exactly it is all about.

Some are urging the government to use the scope of the patent as a basis in legalizing the use of pot in the states. Others who understand the scope of the patent called those in the government who are still against the promulgation of marijuana legalization in some states as hypocrites.

Patent 6630507: Exposing the Truth and Impact to the Pot Industry

For the many who are still baffled on the scope of the famed Patent No. 6630507 were referred to the US Department of Health and Human Services. According to the scope of the intellectual property given to the said department on 2003, this patent covers the potential use of the chemical compounds that can be found in the cannabis plant. It also includes the study on cannabis and its possibilities to protect the brain from damage or degeneration due to some diseases such as Alzheimer’s Disease and Cirrhosis.

Although they aim only to use the non-psychoactive cannabinoids component, critics are still fast to point out that if the government doesn’t believe in the potentials of marijuana as a natural medicine, why do they patent cannabis the way the scope defined it?

READ  New Study Says Mixing Alcohol and Marijuana Can Lead to Problems

Sam Mendez, a public policy lawyer and currently serving as the Executive Director of the University of Washington’s Cannabis Law and Policy Project, stated that it was clearly indicated in the Federal Law that cannabis has no accepted medical use. If that’s the case, the government seemed to be hypocritical for owning a patent that contradicts the perception of the Federal Law.

So the question now lies on what could be the possible impact of the patent no. 6630507 to the pot industry? In many aspects, since the government owns all the legal rights in testing and experimenting cannabis for medical uses, other private companies can only rely on the results provided by the government. They can’t conduct their private experimentation if it goes beyond the legal boundaries of the patent owned by the government.

Marijuana advocates also stressed out that if the government applied and legally owned the patent about medical marijuana, they should have the decency to use this as a basis of the medical benefits, and as a factor in extending the criminal boundaries of marijuana. This can be a good reason for finally implementing legalization of cannabis not just in some states but all throughout the US.

Most of the states that legalized marijuana accepted the usage of the plant for recreational purposes only and subject to some prohibitions and regulations. With this patent, they should extend the usage for medical purposes as well.

 

http://www.marijuananewsonline.com/latest-news/patent-6630507-exposing-truth-impact-pot-industry/


Leave a comment

New Book by Dr. Grotenhermen. Cannabis against cancer: The state of science and practical implications for therapy. Release Date: July 1, 2017th

by Dr. med. Franjo Grotenhermen  http://dr-grotenhermen.de/

In the past 20 years, many cellular and animal studies have been conducted to investigate which cannabinoids in which cancers are effective and could fight as cannabinoids cancer. Cannabinoids inhibit cancer growth at different levels. These include the inhibition of cancer growth through apoptosis, the suicide program of the cells, the inhibition of cancer cell proliferation, inhibition of blood vessel formation, inhibition of metastasis and the strengthening of the immune system against cancer cells.

Causation of cancer cell death and reducing cancer growth

In 2000, a research group was able to demonstrate at the Complutense University in Madrid that THC apoptosis in glioblastoma cells, very aggressive brain cancer cells caused. This was later proved to other cancers. Moreover, cannabinoids can also inhibit the growth of cancer cells in certain cancers such as melanoma, breast cancer and prostate cancer in addition to the induction of apoptosis. Remarkably, cannabinoids do not affect the viability of normal, non-transformed cells.

Interestingly, CBD that binds only weakly to cannabinoid receptors, and other cannabinoids promotes apoptosis in cancer cells. This effect is independent of CB1 and CB2 receptors. The mechanisms caused by the CBD, this effect is not yet fully understood.

Inhibition of blood vessel formation

The formation of blood vessels is critical to the growth of tumors beyond a size of 1 to 2 mm. In cancer cells, cannabinoids block the formation of new blood vessels in which they inhibit a specific growth factor (vascular endothelial growth factor). This and other mechanisms cause the vessel formation in tumors normalized. It will then be smaller and less blood vessels produced. Besides THC and CBD, a number of synthetic cannabinoids inhibit the formation of blood vessels in animal experiments with various types of cancer.

Inhibition of metastasis

The activation of CB1 or CB2 receptor agonists (or both) also reduces the formation of secondary tumors (metastases) in animal models. This includes support for the migration ability (migration) of cancer cells, their ability to attach to other tissues (adhesion) and their ability to penetrate tissue (invasion), inhibited. This has been demonstrated for glioblastoma cells, breast, lung, and cervical cancer cells in cultures.

in various animal models of cancer also CBD, which acts independently of CB1 and CB2 receptors, has the ability to inhibit metastasis. An important role in metastasis plays the inhibition of DNA binding, so-called Ids. In one study, incubation of breast cancer cells to CBD led to a reduction of Id-1, which inhibited their invasiveness.

Regulation of anti-tumor immunity

 

The activation of cannabinoid receptors may lead to changes in the immune system to fight cancer. These changes are called especially the increased production of anti-inflammatory messenger substances (cytokines) in the immune system and the increased formation of regulatory T cells, and suppressor T cells. Regulatory T cells are important for the suppression of unwanted immune processes. They therefore protect against autoimmune diseases and may otherwise be used by tumor cells to escape attacks the immune system. Therefore, there are reports of tumor formation was promoted by the activation of CB2 receptors in which the tumor monitoring has been impaired by the immune system.

On the other hand cannabinoids can also improve the tumor surveillance by the immune system under certain conditions. Thus, the antitumor effect of cannabinoids through the activation of CB2 receptors against melanoma in mice with normal immune systems in a study for example, was stronger than in mice with suppressed immune systems. So cannabinoids can be successfully used against cancer, the tumor-inhibiting effects must be stronger than the immune-suppressive and tumor growth potentially promoting effects.

Detailed information: New Book by Dr. Grotenhermen. Cannabis against cancer: The state of science and practical implications for therapy. Release Date: July 1, 2017th


Leave a comment

Updates from Isodiol: Pure, Natural CBD

Updates from

Isodiol

Pure, Natural CBD

In the 06/13/2017 edition:

Isodiol International announces closing of 100% of a cannabis-infused beverage company, Pot-O-Coffee

Jun 12, 2017 01:26 am
June 12, 2017 – Vancouver, Canada – Isodiol International In.c (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol Interational”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products, today announced that it has completed the transaction of a definitive agreement to acquire the assets of a cannabis-based beverage company […]

The post Isodiol International announces closing of 100% of a cannabis-infused beverage company, Pot-O-Coffee appeared first on Isodiol.
Read in browser »
share on Twitter Like Isodiol International announces closing of 100% of a cannabis-infused beverage company, Pot-O-Coffee on Facebook

Laguna Blends Inc. announces name change and ticker symbol change

Jun 09, 2017 10:53 am
June 7, 2017 – Vancouver, Canada – Laguna Blends Inc. (CSE: LAG) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Laguna”) is pleased to announce that, following its previously announced acquisition of ISO International, LLC on May 15, 2017, the Company will be changing its name to “Isodiol International Inc.” (the “Name Change”) and Canadian Securities […]

The post Laguna Blends Inc. announces name change and ticker symbol change appeared first on Isodiol.
Read in browser »
share on Twitter Like Laguna Blends Inc. announces name change and ticker symbol change on Facebook